Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.52M
Average 0.39M
SION Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Sionna Therapeutics, Inc.NASDAQ: SION
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash dips below year-ago levels
Q1 FY2026 net change in cash of $4.87M fell 89.1% year over year, behind the +33882.5% change in trailing-twelve-month net change in cash. Sequentially, it fell 36.1% from the prior quarter. Over 3 fiscal years it compounded at -23.1% a year.
Context
- Net change in cash increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -89.1% toward the trailing-twelve-month pace of +33882.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- 20.66M USD
- Year-over-year change
- +2919.1%
- 3-year CAGR
- -23.1%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.66M | +2919.1% |
| FY2024 | 2024-12-31 | (733K) | +95.5% |
| FY2023 | 2023-12-31 | (16.32M) | -135.8% |
| FY2022 | 2022-12-31 | 45.52M | — |
Net Change in Cash vs competitors
How SION compares with its peers on the latest reported figures
- SION's LTM Mar 2026 net change in cash of $19.37M is the 8th largest of the 11 companies compared; the peer median is $78K.
- Its year-over-year change of +33882.5% is the highest of 11, against a peer median of +134.7%.
- Over three fiscal years its annual growth of -23.1% compares with a peer median of -31.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $95.61M | -136.2% | -57.8% | 478.0% | |
| LTM Jun 2026 | $71.63M | +197.7% | -7.7% | — | |
| LTM Sep 2026 | $59.8M | -151.0% | — | — | |
| LTM Mar 2026 | $53.21M | +1322.6% | -12.7% | 16.9% | |
| LTM Sep 2026 | $35.63M | +161.9% | — | 13.4% | |
| LTM Sep 2026 | $27.72M | +163.7% | -31.0% | 40.8% | |
| LTM Mar 2026 | $21.92M | -84.2% | — | 101.4% | |
| LTM Mar 2026 | $19.37M | +33882.5% | -23.1% | — | |
| LTM Sep 2026 | $9.09M | +2409.7% | — | 8111.6% | |
| LTM Mar 2026 | $401K | +107.5% | -49.4% | 0.1% | |
| LTM Jun 2026 | $245K | -101.0% | — | — | |
| Peer median (excluding SION) | $78K | +134.7% | -31.0% | 40.8% | |
Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Sionna Therapeutics, Inc.
NASDAQ:SION
Intrinsic Alpha fair value
Locked
Current Price
$2.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.